{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:16:21Z","timestamp":1794564981533,"version":"4.9.1"},"reference-count":36,"publisher":"Kurume Medical Journal","issue":"3.4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kurume Med. J."],"published-print":{"date-parts":[[2014,1,31]]},"DOI":"10.2739\/kurumemedj.ms63001","type":"journal-article","created":{"date-parts":[[2014,5,25]],"date-time":"2014-05-25T22:55:42Z","timestamp":1401058542000},"page":"89-97","source":"Crossref","is-referenced-by-count":17,"title":["Association between Thromboembolic Events and the <I>JAK2<\/I> V617F Mutation in Myeloproliferative Neoplasms"],"prefix":"10.2739","volume":"60","author":[{"given":"YUKA","family":"TAKATA","sequence":"first","affiliation":[{"name":"Department of Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RITSUKO","family":"SEKI","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TAISUKE","family":"KANAJII","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MASAYUKI","family":"NOHARA","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SATOKO","family":"KOTEDA","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KUNIKI","family":"KAWAGUCHI","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KEI","family":"NOMURA","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TAKAYUKI","family":"NAKAMURA","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SATOSHI","family":"MORISHIGE","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EIJIROU","family":"OKU","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KOICHI","family":"OSAKI","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EMICHITOSHI","family":"HASHIGUCHI","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FUMIHIKO","family":"MOURI","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KOJI","family":"YOSHIMOTO","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KOJI","family":"NAGAFUJI","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TAKASHI","family":"OKAMURA","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1445","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kralovics R, Passamonti F, Buser AS, Teo SS, Skoda RC et al. A Gain-of-Function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352:1779-90.","DOI":"10.1056\/NEJMoa051113"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Baxter E, Scott LM, Campbell P, East C, Fourouclas N et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054-61.","DOI":"10.1016\/S0140-6736(05)74230-6"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends in Molecular Medicine 2005; 11:1471-4914.","DOI":"10.1016\/j.molmed.2005.10.003"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011; 118(7):1723-1735.","DOI":"10.1182\/blood-2011-02-292102"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Levine RL, Wernig G. Role of JAK-STAT Signaling in the Pathogenesis of myeloproliferative disorders. Hematology 2006; 233-239.","DOI":"10.1182\/asheducation-2006.1.233"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH. Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006; 107:4274-4281.","DOI":"10.1182\/blood-2005-12-4824"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Li J, Kent DG, Chen E, Green AR. Mouse models of myeloproliferative neoplasms: JAK of all grades. Disease Models & Mechanisms 2011; 4:311-317.","DOI":"10.1242\/dmm.006817"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Scott LM, Tong W, Levine RL, Scott MA, Green AR et al. JAK2 Exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356:459-68.","DOI":"10.1056\/NEJMoa065202"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Siemiatkowskaa A, Bieniaszewskab M, Hellmannb A, Limona J. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms. Leukemia Research 2010; 34:387-389.","DOI":"10.1016\/j.leukres.2009.06.017"},{"key":"10","unstructured":"10. Hussein K, Wahab OA, Lasho TL, Van Dyke DL, Levine RL et al. Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms. Leukemia 2003; 17:637-641."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. James C, Ugo V, Le Coue’dic JP, Staerk J, Casadevall N et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 2005; 34:1144-1148.","DOI":"10.1038\/nature03546"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Hussein K, Bock O, Kreipe H. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: Persistence of old questions despite new answers. Pathobiology 2007; 74:72-80.","DOI":"10.1159\/000099120"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Wadleigh M, Tefferi A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol 2010; 91:174-179.","DOI":"10.1007\/s12185-010-0529-5"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Büller HR et al. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review. Thrombosis Research 2009; 124:409-417.","DOI":"10.1016\/j.thromres.2009.02.004"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Linnemann B, Kraft C, Roskos M, Zgouras, Lindhoff-Last E. Inferior vena cava thrombosis and its relationship with the JAK2V617F mutation and chronic myeloproliferative disease. Thrombosis Research 2012; 129:720-724.","DOI":"10.1016\/j.thromres.2011.09.011"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Austin SK, Lambert JR. The JAK2V617F mutation and thrombosis. Br. J. Haematology 2008; 143:307-320.","DOI":"10.1111\/j.1365-2141.2008.07258.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood 2013; 122:2176-2184.","DOI":"10.1182\/blood-2013-03-460154"},{"key":"18","unstructured":"18. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA et al. WHO classification of tumors of haematopoietic and lymphoid tissues. WHO press 2008; 76-86."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Tanaka R, Kuroda J, Stevenson W, Kimura S, Ishikawa T et al. Fully automated and super-rapid system for the detection of JAK2V617F mutation. Leukemia Research 2008; 32:1462-1467.","DOI":"10.1016\/j.leukres.2007.12.019"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7:387-397.","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Dan K, Yamada T, Kimura Y, Usui N, Okamotoet al. Clinical Features of Polycythemia Vera and Essential Thrombocythemia in Japan: Retrospective Analysis of a Nationwide Survey by the Japanese Elderly Leukemia and Lymphoma Study Group. Int J Hematol. 2006; 83:443-449.","DOI":"10.1532\/IJH97.06009"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ohyashiki K, Ito Y, Hori K, Sato K, Makino T et al. Thrombosis can occur at any phase of essential thrombocythemia with JAK2V617F mutation: a single institutional study in Japan. Leukemia 2007; 21:1570-1571.","DOI":"10.1038\/sj.leu.2404666"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007; 33(4):313-320.","DOI":"10.1055\/s-2007-976165"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Lee HS, Park LC, Lee EM, Lee WS, Kim Y S et al. Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from korea. Clinical Lymphoma, Myeloma & Leukemia 2012; 12-1:70-75.","DOI":"10.1016\/j.clml.2011.10.002"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007; 109:2446-2452.","DOI":"10.1182\/blood-2006-08-042515"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Carobbio A, Finazzi G, Guerini V, Barbui T. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007; 109:2310-2313.","DOI":"10.1182\/blood-2006-09-046342"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. De Stefano V, Za T, Rossi E, Vannucchi A M, Ruggeri M et al. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. Ann Hematol 2010; 89:141-146.","DOI":"10.1007\/s00277-009-0788-5"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization essential thrombocythemia (IPSET-thrombosis). 2012; 120:5128-5133.","DOI":"10.1182\/blood-2012-07-444067"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Passamonti F, Rumi E, Pietra D, Lazzarino M, Cazzola M et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010; 24:1574-1579.","DOI":"10.1038\/leu.2010.148"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Maugeri N, Baldini M, Ramirez GA, Rovere-Querini P, Manfredi AA. Platelet-leukocyte deregulated interactions foster sterile inflammation and tissue damage in immune-mediated vessel diseases. Thrombosis Res 2012; 129:267-273.","DOI":"10.1016\/j.thromres.2011.12.001"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366:1945-53.","DOI":"10.1016\/S0140-6736(05)67785-9"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Falanga A, Marchetti M, Vignoli A, Balducci D, Russo et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematology 2007; 35:702-711.","DOI":"10.1016\/j.exphem.2007.01.053"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Robertson R, Urquhqrt C, Ford I, Townend J, Watson HG et al. Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2V6I7F status, clonality, and antiphospholipid antibodies. J Thrombosis and Haemostasis 2007; 5:1679-1685.","DOI":"10.1111\/j.1538-7836.2007.02626.x"},{"key":"34","unstructured":"34. Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, Cervantes F, Colomer D et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006; 91:169-175."},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Caielli S, Banchereau J, Pascual V. Neutrophils come of age in chronic inflammation. Current Opinion in Immunology 2012; 24:671-677.","DOI":"10.1016\/j.coi.2012.09.008"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Vannucchi AM. JAK2 mutation and thrombosis in the myeloproliferative neoplasms. Curr Hematol Malig Rep 2010; 5:22-28.","DOI":"10.1007\/s11899-009-0038-x"}],"container-title":["The Kurume Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kurumemedj\/60\/3.4\/60_MS63001\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T05:06:27Z","timestamp":1725080787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kurumemedj\/60\/3.4\/60_MS63001\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,31]]},"references-count":36,"journal-issue":{"issue":"3.4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2739\/kurumemedj.ms63001","relation":{},"ISSN":["0023-5679","1881-2090"],"issn-type":[{"value":"0023-5679","type":"print"},{"value":"1881-2090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,31]]},"article-number":"MS63001"}}